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Abstract: Liver X receptors (LXRs) have been increasingly recognized as a potential therapeutic
target to treat pathological conditions ranging from vascular and metabolic diseases, neurological
degeneration, to cancers that are driven by lipid metabolism. Amidst intensifying efforts to discover
ligands that act through LXRs to achieve the sought-after pharmacological outcomes, several lead
compounds are already being tested in clinical trials for a variety of disease interventions. While more
potent and selective LXR ligands continue to emerge from screening of small molecule libraries,
rational design, and empirical medicinal chemistry approaches, challenges remain in minimizing
undesirable effects of LXR activation on lipid metabolism. This review provides a summary of
known endogenous, naturally occurring, and synthetic ligands. The review also offers considerations
from a molecular modeling perspective with which to design more specific LXRβ ligands based
on the interaction energies of ligands and the important amino acid residues in the LXRβ ligand
binding domain.
Keywords: liver X receptors; LXRα; LXRβ specific ligands; atherosclerosis; diabetes; Alzheimer’s
disease; cancer; lipid metabolism; molecular modeling; interaction energy

1. Structure and Functions of Liver X Receptors
Nuclear receptors (NRs) are one of the most abundant classes of transcriptional regulators in
animals. They regulate diverse biological functions including homeostasis, reproduction, development
and metabolism, in normal as well as in pathological settings. Nuclear receptors are also known
as hormone receptors (HRs) that are ligand-activated transcription factors, providing a direct link
between signaling molecules that control these processes and transcriptional responses [1]. In all,
NRs comprise a group of 48 ligand-activated transcription factors in humans.
The liver X receptors (LXRs) are NRs that act as oxysterol sensors, regulating genes involved in
cholesterol and lipid metabolism. Based on the coding genes LXRs are classified as LXRα (NR1H3)
and LXRβ (NR1H2) [2]. LXRα is expressed most highly in the liver and to a lesser extent in the kidney,
small intestine, spleen, and adrenal gland [3,4]. In contrast, LXRβ is ubiquitously expressed [5].
LXRα consists of 447 [4] and LXRβ contains 461 [6] amino acids. The LXR molecules can be viewed
as having four functional domains: (1) an amino-terminal ligand-independent activation function
domain (AF-1), which may stimulate transcription in the absence of ligand; (2) a DNA-binding domain
(DBD) containing two zinc fingers; (3) a hydrophobic ligand-binding domain (LBD) required for ligand
binding and receptor dimerization; and, (4) a carboxy-terminal ligand-dependent transactivation
sequence (also referred to as an activation function-2 (AF-2) domain) that stimulates transcription
in response to ligand binding [7]. The DBD and LBD regions of LXRα and LXRβ have 75.6% and
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74% sequence identity, respectively [8]. The LBD of LXRα features a three-layered α-helical sandwich
structure common to all known nuclear receptors and contains ten α-helices [9]. Both LXRα and LXRβ
function as heterodimers with the retinoid X receptor (RXR). LXR/RXR is a “permissive heterodimer”
that may be activated by either LXR agonist or 9-cis retinoic acid, a specific RXR ligand. The LXR/RXR
complex binds to an LXR responsive element (LXRE) in the promoter region of target genes
which consists of two direct repeats of hexameric nucleotides, AGGTCA, separated by four or one
nucleotide(s) (DR4 or DR1) [10]. It is through these target genes that LXR regulate various biological
processes that are implicated in normal as well as pathological functions. Numerous LXR target
genes have been identified such as ATP binding cassette (ABC) transporter isoforms A1, G1, G5, and
G8, apolipoprotein E (ApoE), cholesteryl ester transfer protein (CETP), fatty acid synthase (FAS),
cytochrome P450 isoform 7A1 (CYP7A1)—cholesterol 7α-hydroxylase, and carbohydrate regulatory
element binding protein (ChREBP) [11].
The main function of LXRs is the regulation of cholesterol metabolism. Agonists of LXRs increase
insulin sensitivity and stimulate insulin secretion. Activation of LXRs inhibits inflammation and
autoimmune reactions. Moreover, pharmacological studies and genetic manipulations indicate that
LXRs inhibit atherogenesis [12]. LXRs are also involved in the regulation of renin secretion [13],
inhibition of amyloid b formation in the central nervous system [14], regulation of gonadal function
and steroidogenesis both in gonads and in adrenals [15], proliferation and differentiation of
keratinocytes [16], and inhibition of tumor cells proliferation [17]. LXR regulation of transcription
activity can be explained by four different models- ligand independent repression, direct activation,
ligand dependent activation and trans-repression. The specific activation/repression of gene
transcription by LXRs is cell and gene dependent. In the absence of an agonist, the LXR-RXR heterodimer
inhibits transcription by the recruitment of co-repressors N-CoR (nuclear receptor corepressor) and
SMRT (silent mediator of retinoic acid receptor and thyroid receptor) [10,18]. Ligand binding initiates the
dissociation of the co-repressors resulting in a moderate activation leading to stimulation of transcription.
Ligand binding is followed by recruitment of co-activators and in this state the transcription levels
are the highest. In the trans-repression model, LXRs have the capability of negatively regulating the
expression of inflammatory genes. While the mechanism of such trans-repression is not completely
understood, the process is known to involve the inhibition of inflammatory responses to cytokines
via blockade of the activity of the signal transducer and transcription activator nuclear factor NF-κB,
and activator protein 1 that induce transcription of the proinflammatory genes COX2, MMP9, IL-6,
MCP-1, iNOS, IL-1β [19–24]. Consequently, alterations in endogenous LXR activity is evidenced in
many pathological conditions such as atherosclerosis, cancer, neurological disorders such as multiple
sclerosis, Alzheimer disease and Parkinson disease, arthritis and skin diseases (Figure 1).
1.1. LXR and Atherosclerosis
The physiological ligands of LXR are the oxysterols that are produced endogenously by
enzymatic reactions, by reactive oxygen species (ROS)-dependent oxidation of cholesterol and by the
alimentary processes. The high affinity of oxysterols to LXRs has defined their physiological role as
“cholesterol sensors”. The ligand bound LXRs increase the expression of target genes associated
with reverse cholesterol transport, cholesterol conversion to bile acid, and intestinal cholesterol
absorption. Some of these genes are the ATP-binding cassette (ABC) transporters A1 and G1,
the sterol response element-binding protein-1c (SREBP-1c), the apolipoprotein E, phospholipid
transport protein, cholesterol 7α-hydroxylase and several other genes involved in lipogenesis such as
FAS and stearoyl-CoA desaturase (SCD) [25–31]. LXRα-knockout mice on high cholesterol diet when
subjected to genetic studies showed defects in cholesterol metabolism in the liver and a corresponding
increase in plasma cholesterol levels indicating the therapeutic role of LXR agonists in atherosclerosis.
Treatment with LXR agonists resulted in attenuation of atherosclerosis in vivo with a reduction in total
cholesterol and/or elevation in high density cholesterol [28,32–37]. The upregulation of the lipogenesis
genes by LXR increased plasma and hepatic triglyceride (TG) levels in mice and lipid accumulation in
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human mature adipocytes. Studies using LXR agonists have shown that the antiatherosclerotic effects
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Figure 1. Liver X Receptors may be related to various pathological conditions.
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LXR effect on endothilial cholesterol homeostasis that mediates an impaired VEGFR2 compartmentation
and signaling. Thus changes in endothelial cholesterol have an effect on VEGFR2 signaling due to
the interactions of LXR with the complex signaling pathways within the lipid rafts/caveolae. LXRβ
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24(S)-hydroxycholesterol, also known as cerebrosterol because of its abundance in brain, is
synthesized by 24-hydroxylase. It was proven to be an efficient activator of LXR regulated gene
ABCA1 [57,58]. 27-hydroxycholesterol is generated from cholesterol by the P450 enzyme sterol
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24(S)-hydroxycholesterol, also known as cerebrosterol because of its abundance in brain, is
synthesized by 24-hydroxylase. It was proven to be an efficient activator of LXR regulated gene
ABCA1 [57,58]. 27-hydroxycholesterol is generated from cholesterol by the P450 enzyme sterol
27-hydroxylase which is encoded by Cyp27a1. It is further oxidized to aldehyde and carboxylic acid
(cholestenoic acid) by 27-hydroxylase. Both the 27-hydroxycholesterol and cholestenoic acid are the
ligands for
LXRs
[59–61].
25-hydroxycholesterol, synthesized by 25-hydroxylase, is a potent
Molecules
2017,
22, 88
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Prostaglandin F2α (PGF2α) is one of the cyclooxygenase metabolites of arachidonic acid. PGF2α
antagonized the T0901317 induced activation of LXRα-LBD and LXRβ-LBD in a dose dependent
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in a dose dependent manner there by inhibits the LXRα [69]. 5α,6α-Epoxycholesterol (5,6-EC) is
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a product of cholesterol auto oxidation found in the human circulation and atherosclerotic lesions.
In an LXR-cofactor interaction assay, 5,6-EC bound directly to LXR-LBD and disrupted the recruitment
of a number of cofactors to both LXRα and LXRβ. 5,6-EC also exhibits the antagonist behavior with
Molecules 2017,
22, 88[70].
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Table 1. EC50 values of selected phytosterols evaluated in a coactivator peptide recruitment assay.
EC50 (nM)

Phytosterol
Sitosterol
Campesterol
Fucosterol
Sitostanol
Campestenol
GW3965A

LXRα

LXRβ

42
43
33
136
122
197

26
28
42
110
124
41

Fucosterol, a sterol abundant in marine algae, has hypocholesterolemic effects and increases
plasma high-density lipoprotein (HDL) activity. Fucosterol significantly induced the transactivation of
both LXRα (+155% at 200 µM; p < 0.05) and LXRβ (+83% at 200 µM; p < 0.05) in HEK 293 cells [75].
In HepG2 cells, fucosterol (200 µM) increased ABCA1, ABCG1, ABCG5, ABCG8 and cholesteryl ester
transfer protein (CETP) mRNA expression by 2.4-, 13.2-, 1.5-, 1.3- and 0.8-fold (p < 0.05) respectively.
YT-32 ((22E)-ergost-22-ene-1α,3β-diol), derived from ergosterol or brassicasterol, directly binds
to LXRα and stimulates the interaction of LXRα with ACTR and DRIP205 at a 10 µM concentration.
It also activates the LXRβ with an EC50 value of 1.1 µM. Unlike the synthetic LXR agonist T0901317,
YT-32 inhibits intestinal cholesterol absorption without increasing plasma triglyceride levels. Thus,
YT-32 selectively modulates intestinal cholesterol metabolism [76].
Diterpenes are natural steroids that are widely distributed in plants and insects (Figure 4 and
Table 2). Acanthoic acid (AA) is a pimaradiene diterpene, isolated from the root bark of Acanthopanax
koreanum Nakai. AA activates LXRα and LXRβ and modulates CCl4 -induced liver fibrosis in animals
by inhibiting NF-κB translocation. AA has also been found to inhibit growth of rat hepatic stellate
cells (HSC-T6) via activation of LXR [77].
Table 2. LXR activities of diterpenoids, steroids and triterpenoids.

Name

Acanthoic acid
Viperidone
Polycarpol
Gorgostone Derivative

LXR SPA Binding
IC50 (µM)

Cofactor Association
HTRF * Assay, EC50 (µM)

Transactivation Max.
Fold Induction

LXRα

LXRβ

LXRα

LXRβ

LXRα

LXRβ

0.25
0.10
0.12
0.07

1.49
—
≥15
0.2

0.18
≥15
0.030
0.05

≥50
—–
≥50
—-

15.9 (100 µM)
——–
13 (10 µM)

5.6 (100 µM)
——–
2.2 (10 µM)

* HTRF assay: Homogeneous Time Resolved Fluorescence assay.

Traves et al. reported that stimulation of macrophages with acanthoic acid-related diterpenes
(DTP 1-5) induces the expression of LXR target genes and cholesterol efflux to a similar level observed
with synthetic agonists like GW3965 and T0901317 [78]. Using a scintillation proximity assay, acanthoic
acid, polycarpol, gorgostane derivatives and viperidone derivatives selectively activate LXRα in
HEK293 cells, as shown in Table 2 [79].
Several natural ligands isolated from herbal medicines (Figure 5) have also shown activities
towards LXRs (Table 2). For example, gynosaponin TR1 ((20S)-2α,3β,12β,24(S)-pentahydroxydammar25-ene 20-O-β-D-glucopyranoside), a dammarane saponin which is isolated from Chinese herbal
medicine Gynostemma pentaphyllum, is an LXR agonist. It also exhibits selective activity towards LXRα
over LXRβ. In HEK293 cells, gynosaponin TR1 induced a significant elevation of luciferase activity for
LXRα at 10 µM concentration. It also enhanced the expression of ABCA1 and ApoE gene in THP-1
derived macrophages at the same concentration levels, which promotes the cholesterol efflux [80].
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Podocarpic acid is a natural non-steroidal LXR agonist derived from plant resins [81]. From the
Podocarpic
acid
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LXR
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derived
from plant
[81]. From
the
LXR
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proximal
binding
assays it was
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derivatives
such as
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was
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that
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derivatives
such
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itstransactivation
dimer anhydride
andon
imides
binds
to indicate
both LXRα
LXRβ at 1–2
nMexhibited
concentrations.
based
studies
HEK-293
cells
that and
the anhydride
dimer
the EC50Cell
value
of
transactivation
studies
on HEK-293
cells indicate
themaximal
anhydride
dimer exhibited
ECreceptors,
50 value of
1 nM against both
receptors
and showed
50- andthat
8-fold
induction
of α and βthe
LXR
1 nM
against both
andand
showed
and increases
8-fold maximal
induction
of α and βlevels
LXR receptors,
respectively.
Thereceptors
more stable
potent50imide
the total
plasma cholesterol
by 28%
respectively.
The more
stable
potent imideby
increases
total plasma
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levels
by 28%
with concomitant
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ofand
HDL-cholesterol
22% andthe
decreases
the LDL
by 11% in
hamsters.
with
concomitant
increase
of HDL-cholesterol
22% and decreases
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by 11%byin19%
hamsters.
Similar
results were
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in mice wherebyHDL-cholesterol
levelsthe
were
increased
[82].
SimilarMore
results
were also
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in mice
where
HDL-cholesterol
levels
19% [82].
recently,
it has
been shown
that
honokiol,
extracted from
thewere
bark increased
of Houpuby
(Magnolia
officinalis),
induces LXR
in a reporter
It increases
ABCA1
mRNA
protein
More recently,
it transactivity
has been shown
that assay.
honokiol,
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theand
bark
of levels
Houpu
in a dose-dependent
manner
intransactivity
U251-MG cells
in THP-1
by 3 fold.
Honokiol
increases
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LXR
in aand
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ABCG1
ApoE mRNAmanner
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theirHonokiol
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by
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in aand
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cells and
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7-fold,
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Similarly,
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increases
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of
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the ABCG1 and ApoE mRNA levels in THP-1 macrophage by 2.9- and 3-fold, and their protein levels
macrophages
[84]. [83]. Similarly, honokiol increases expression of the ABCA1 gene in
byperitoneal
4.5- and 7-fold,
respectively
Paeoniflorin
(Paeonia
lactiflora Pall) is one of the active ingredients of Shaoyao, an herbal medicine
peritoneal macrophages [84].
with
anti-hyperlipidemic,
neuroprotective,
and
effects.
Reporteran
assays
show
that
Paeoniflorin (Paeonia lactiflora
Pall) is one
of anti-hepatofibrosis
the active ingredients
of Shaoyao,
herbal
medicine
paeoniflorin
transactivates
the
GAL4
promoter
with
an
EC
50 value of 8.7 µM. It also transactivates the
with anti-hyperlipidemic, neuroprotective, and anti-hepatofibrosis effects. Reporter assays show that
PLTP promoter,
ABCA1 promoter
rat CYP7A1
promoter
withof
EC
50 values of 21.6 µM, 11.9 µM,
paeoniflorin
transactivates
the GAL4and
promoter
with an
EC50 value
8.7
µM. It also transactivates the
and 66 µM, respectively [85]. These results suggest that paeoniflorin may act as an LXRα agonist.
PLTP promoter, ABCA1 promoter and rat CYP7A1 promoter with EC50 values of 21.6 µM, 11.9 µM,
and 66 µM, respectively [85]. These results suggest that paeoniflorin may act as an LXRα agonist.
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Iristectorigenin B, isolated from Shegan (Belamcanda chinensis), significantly induced the
transcriptional activity of both LXRα (+540%) and LXRβ (+331%) at 20 µM in a dose-dependent manner.
Iristectorigenin B increased cholesterol efflux to HDL and reduced cellular cholesterol concentration in
macrophages. It also significantly increased the mRNA expression levels of both ABCA1 and ABCG1
LXR-responsive genes by 2.0 and 1.9-fold at 10 µM concentration, respectively [86].
Ethyl 2,4,6-trihydroxybenzoate (ETB) was isolated from Celtis biondii and was shown to directly
bind to and stimulate the transcriptional activity of LXRα and LXRβ. ETB significantly induced the
transactivation of both LXRα (+64%) and LXRβ (+55%) at 100 µM with an EC50 values of 80.76 and
37.8 µM, respectively. ETB increased the cholesterol efflux to HDL and reduced cellular cholesterol
concentration in THP-1, RAW 264.7 macrophages and intestinal cells in a dose dependent manner.
At a concentration of 100 µM, ETB increased ABCA1 mRNA expression by 7.4-fold for THP-1-derived
macrophages and 2.1-fold for RAW 264.7 macrophages, respectively, without inducing lipid increase
in HepG2 cells [87].
Cyanidin, a natural flavonoid found in many fruits and vegetables, is known to regulate cellular
lipid metabolism. Cyanidin induced the transactivation of LXRα by 32% (at 50 µM), 59% (at 100 µM)
and LXRβ by 33% (at 100 µM). The KD values of cyanidin with LXRα and LXRβ were measured
at 2.16 and 73.2 µM, respectively. Cyanidin activates the LXRα with an EC50 value of 3.48 µM and
LXRβ at 125.2 µM. Cyaniding also activated LXR responsive genes including ABCA1, SREBP-1c and
ABCG5 by 2.5 fold (100 µM), 3.6-fold (100 µM) and 1.4-fold (100 µM), respectively. It also reduced
the concentrations of cellular TG by 21% and 23% in THP-1 and HepG2 cells, respectively at 100 µM
concentration [88].
Cineole, a small aroma compound present in teas and herbs, has been shown to stimulate the
transactivation of LXRs. Treatment of CHO-K1 cells with cineole induced the transactivation of LXRα
by more than 75% and LXRβ by over 100%. In RAW 264.7 macrophages, cineole was able to reduce
cellular cholesterol levels. Cineole also significantly increased the mRNA expression of the LXR
responsive genes. Surprisingly, in hepatocytes that were stimulated with cineole, LXR responsive
genes FAS, SREBP-1c and SCD-1 were markedly downregulated. These results suggest that cineole is
acting like a partial agonist which selectively activates LXRs without inducing hepatic lipogenesis [89].
Apart from the plants and herbal derivatives, some fungal derivatives such as paxillin and
ergostan-4,6,8,22-tetraen-3-one, an erostane derivative (isolated from Norwegian soil) have also been
shown to possess agonist activities towards LXRs [90].
2.3.2. Natural Antagonists
While the main focus of LXR ligand development in the past 10 years has been on therapeutically
useful agonists, several naturally occurring antagonists have emerged in recent reports that
demonstrated the ability to reduce triglycerides and improve fatty liver conditions, suggesting potential
utility of LXR antagonists as therapeutic agents.
Figure 6 shows a few naturally occurring compounds that act as LXR antagonists. Guttiferone
inhibits the activity of LXRα with an IC50 value of 3.4 µM and that of LXRβ with an IC50 value of
>15 µM, which indicates the 5-fold selectivity towards LXRα. However, guttiferone did not show any
LXR activity in coactivation assays [91]. Riccardin C (RC) and riccardin F (RF) are non-sterol natural
LXR antagonists isolated from liverwort Blasia pusilla. RC is a selective antagonist of LXRβ and can
enhance ABCA1 expression and cellular cholesterol efflux in THP-1 macrophages by 2-fold, ABCG1 by
2.6-fold, SREBP-1c by 1.6-fold at 10 µM concentration. Riccardin F is a natural dual antagonist for both
LXR isoforms [92].
Naringenin is a flavonoid that can be found in grapefruit, oranges and tomatoes. Goldwasser et al.
confirmed that naringenin displayed antagonist activities towards LXRα in the presence of LXRα
agonist T0901317. It inhibited the LXRα activity by 28.4% at 126 µM and 39.1% at 400 µM concentrations
in HEK 293 T cells which were stimulated with 4.7 nM T0901317. It also reduced the abundance of
mRNA of ABCA1, ABCG1, HMGR and FAS genes by 92%, 27%, 43%, and 41% respectively [93].
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[95]. Dahuang (Rheum palmatum L.) contains an anthraquinone-like
ingredient, rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid) that was discovered to exhibit
The Chinese herbal medicine Dahuang (Rheum palmatum L.) contains an anthraquinone-like
antagonistic activities toward both LXRs [96]. The luciferase activity assays showed that rhein
ingredient, rhein (4,5-dihydroxyanthraquinone-2-carboxylic acid) that was discovered to exhibit
dose-dependently inhibited the transcriptional activity of LXRα and LXRβ stimulated by the agonist
antagonistic activities toward both LXRs [96]. The luciferase activity assays showed that rhein
GW-3965. This suggests that rhein inhibits the expression of SREBP-1c or its target genes in the liver [96].
dose-dependently inhibited the transcriptional activity of LXRα and LXRβ stimulated by the agonist
Kanaya et al. reported that the fatty acid biosynthesis pathways were downregulated in mouse
GW-3965. This suggests that rhein inhibits the expression of SREBP-1c or its target genes in the liver [96].
livers treated with white button mushroom (WBM). The LXR luciferase activity was significantly
Kanaya when
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Kuding tea extract revealed its antagonist property. The mRNA expression of LXRβ targets genes
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including ABCA1, ABCG1, LPL and ApoE, were significantly inhibited in the liver and fat tissue in
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Kim et al. reported that methanol extracts (MEH184 and MEH185) of Parthenocissua tricuspidata
Kim
et al. and
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and
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transcriptional
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the expression of FAS, ADD1/SREBP-1c and LXRα mRNA, which have been established to
reduced the expression of FAS, ADD1/SREBP-1c and LXRα mRNA, which have been established to
be LXRα target genes [100].
be LXRα target genes [100].
2.3.3. Synthetic LXR Ligands
2.3.3. Synthetic LXR Ligands
Multiple findings proving LXR’s efficacy in various disease states have driven the development of
Multiple findings proving LXR’s efficacy in various disease states have driven the development of
novel and potent LXR modulators. T0901317 (Figure 7) is a non-steroidal synthetic ligand composed of
novel and potent LXR modulators. T0901317 (Figure 7) is a non-steroidal synthetic ligand composed of
a tertiary sulfonamide and a bistrifluoromethyl carbinol, allowing for vital hydrogen binding activity
a tertiary sulfonamide and a bistrifluoromethyl carbinol, allowing for vital hydrogen binding activity
responsible for activating LXR and recruiting its cofactors [101]. The synthetic ligand has been proven
responsible for activating LXR and recruiting its cofactors [101]. The synthetic ligand has been proven
to to
induce
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anddownregulate
downregulateamyloid-β
amyloid-β
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ABCA1expression,
expression,decrease
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cancer cell
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peptide production. While T0901317 appears to be a very effective LXR activator, the ligand is also an an
activator
ofof
the
pregnane
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synthetic
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RORα and RORγ, putting the selectivity of this particular synthetic ligand into question [102,103].
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synthetic molecules in search for new potent chemical scaffolds to interact within the LXR
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T0901317 and GW3965 have been studied extensively in the activation of LXR, and as
such, multiple research groups and companies have developed novel ligands to compare to the
previous synthetic molecules in search for new potent chemical scaffolds to interact within the LXR
ligand-binding pocket. GlaxoSmithKline has continued to develop these LXR activators with the
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synthesis of GSK3987. GSK3987 is a substituted 3-(phenylamino)-1H-pyrrole-2,5-dione, or a maleimide,
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expression without affecting the plasma triglyceride levels in both mice and cynomolgus monkeys [108].
A new class of LXRβ partial agonists with the introduction of a pyrrole group to a T0901317
A new class of LXRβ partial agonists with the introduction of a pyrrole group to a T0901317
analog has been reported [109]. Two crystal structures, 4DK7 and 4DK8 (Figure 8), reveal that
analog has been reported [109]. Two crystal structures, 4DK7 and 4DK8 (Figure 8), reveal that two
two separate orientations comparing these ligands appear to both seal off the ligand-binding site of LXRβ,
separate orientations comparing these ligands appear to both seal off the ligand-binding site of
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LXRβligands.
ligands.

With the utilization of the structure-based drug design platform, Contour, Zheng et al. synthesized
LXRβ agonists mainly containing a 2-(methylsulfonyl)benzyl alcohol and a piperazine core. One
such compound (514V, Figure 8) exhibited 27 fold selectivity for LXRβ over LXRα, and is currently
in clinical trials for the treatment of atopic dermatitis [112].
More recent studies have seen synthetic agonists that focus on the therapeutic potential
associated with LXR activation and Alzheimer’s disease. Stachel et al. synthesized LXRβ selective
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With the utilization of the structure-based drug design platform, Contour, Zheng et al. synthesized
LXRβ agonists mainly containing a 2-(methylsulfonyl)benzyl alcohol and a piperazine core. One such
compound (514V, Figure 8) exhibited 27 fold selectivity for LXRβ over LXRα, and is currently in
clinical trials for the treatment of atopic dermatitis [112].
More recent studies have seen synthetic agonists that focus on the therapeutic potential associated
with LXR activation and Alzheimer’s disease. Stachel et al. synthesized LXRβ selective agonists
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The mechanism of LXR activation is consistent with activation of other nuclear receptors, such as
Themuch-studied
mechanism estrogen
of LXR activation
is consistent
with activation
of other
nuclear
such as
the
receptor [8,102].
Upon agonist
binding, helix
12, also
knownreceptors,
as activation
the much-studied
estrogen
receptor
[8,102].
Upon
agonist
binding,
helix
12,
also
known
as
activation
function 2 (AF2), assumes a conformation that closes the binding pocket and creates a groove into
function
(AF2), assumes
a can
conformation
that closes
thestructural
binding(crystallographic)
pocket and creates
a groove
which2coactivator
proteins
bind [114]. There
is strong
evidence
that into
which
coactivator
proteins
can bind
[114]. There
is strong
structural
evidence that
closing
of the binding
pocket
is mediated
by an R-H···π
interaction
(R(crystallographic)
= C or N) that is established
upon agonist binding between His435 (helix 11) and Trp457 (helix 12) [101].
The binding pocket is largely hydrophobic with many non-polar aliphatic and aromatic
residues located throughout, as illustrated in Figure 10. There is a hydrophilic region of the binding
pocket possessing several polar and charged amino acids which is, because of its proximity to the
protein surface, solvent accessible. This hydrophilic region is located near helices 1 and 5 and the β-sheet
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closing of the binding pocket is mediated by an R-H···π interaction (R = C or N) that is established
upon agonist binding between His435 (helix 11) and Trp457 (helix 12) [101].
The binding pocket is largely hydrophobic with many non-polar aliphatic and aromatic residues
located throughout, as illustrated in Figure 10. There is a hydrophilic region of the binding pocket
possessing several polar and charged amino acids which is, because of its proximity to the protein
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solvent accessible. This hydrophilic region is located near helices 1 and 5 and the β-sheet
region found between helices 5 and 6. It should also be noted that within the hydrophobic region, on
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Figure 10. The binding pocket of LXRβ based on the optimized 3KFC crystal structure.
Figure 10. The binding pocket of LXRβ based on the optimized 3KFC crystal structure.
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All pairwise binding energy calculations were performed at the BLYP-D/def2-TZVP[118] level
acids fitting this criterion.
of theory using the ORCA molecular electronic structure package [119] through the Cuby4 interface
All pairwise binding energy calculations were performed at the BLYP-D/def2-TZVP [118] level of
[120]. The COSMO implicit solvation method, along with a dielectric constant of 4.0, was used to
theory using the ORCA molecular electronic structure package [119] through the Cuby4 interface [120].
mimic the protein’s interior environment [121]. This approach has been adopted in several previously
Thereported
COSMOstudies
implicit[122,123].
solvation
method, along with a dielectric constant of 4.0, was used to mimic the
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effects ofreported
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studies
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Figure 11 gives pairwise interaction energies of allout
40 ligand-residue
complexes
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using
Amber99
field (http://www.yasara.org).
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seven
crystal force
structures.
Here it is seen that there are 11 particularly strong interactions, those
involving
Phe329—Trp457
the order shown
in of
Figure
11),
exhibiting average
interaction
energies
of
Figure 11
gives pairwise(in
interaction
energies
all 40
ligand-residue
complexes
averaged
across
about
3.0
kcal/mol
or
stronger.
Among
these
11
interactions,
those
involving
Phe329
(−5.66
kcal/mol),
all seven crystal structures. Here it is seen that there are 11 particularly strong interactions, those
Arg319Phe329—Trp457
(−5.11 kcal/mol), (in
Phe271
(−4.87shown
kcal/mol),
and His435
(−4.15 kcal/mol)
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particularly
strong.of
involving
the order
in Figure
11), exhibiting
average
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Interestingly two of these interactions, those associated with Phe329 and Phe271 are completely
hydrophobic interactions while two are polar interactions, namely interactions involving the
positively charged Arg319 and the heterocyclic ring of His435. It should be noted that Arg319 and
His435 are the only two polar residues among the 11 discussed here. Arg319 is one of the residues
located in the hydrophilic region of the binding pocket and is found near the protein surface. As
noted above, the establishment of a strong contact between His435 and Trp457 is believed to play a
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about 3.0 kcal/mol or stronger. Among these 11 interactions, those involving Phe329 (−5.66 kcal/mol),
Arg319 (−5.11 kcal/mol), Phe271 (−4.87 kcal/mol), and His435 (−4.15 kcal/mol) are particularly
strong. Interestingly two of these interactions, those associated with Phe329 and Phe271 are completely
hydrophobic interactions while two are polar interactions, namely interactions involving the positively
charged Arg319 and the heterocyclic ring of His435. It should be noted that Arg319 and His435
are the only two polar residues among the 11 discussed here. Arg319 is one of the residues located
in the hydrophilic region of the binding pocket and is found near the protein surface. As noted
Molecules
22, 88
of 23 in
above,
the2017,
establishment
of a strong contact between His435 and Trp457 is believed to play 15
a role
ligand-mediated LXR agonism. It seems reasonable to hypothesize that direct interactions of the ligand
role in ligand-mediated LXR agonism. It seems reasonable to hypothesize that direct interactions of
with these two amino acids play a strong role in stabilizing the active conformation of the receptor,
the ligand with these two amino acids play a strong role in stabilizing the active conformation of the
although it should be kept in mind that other ligand-residue or ligand-residue-residue interactions
receptor, although it should be kept in mind that other ligand-residue or ligand-residue-residue
may play roles in changing the protein’s conformation.
interactions may play roles in changing the protein’s conformation.

Figure 11. Pairwise interaction energies of 40 amino acids with ligand within the LXRβ binding pocket.
Figure 11. Pairwise interaction energies of 40 amino acids with ligand within the LXRβ binding pocket.

There are 16 ligand-residue interactions, Leu345—Ala343, with moderate interaction energies,
arefrom
16 ligand-residue
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very surprising to encounter these mildly repulsive interactions, which are most likely caused by
that all calculations are based on crystal structures in which only side chain (but not backbone) atoms
steric clashes related to backbone atoms.
are optimized, thus it is not very surprising to encounter these mildly repulsive interactions, which are
Shown in Figure 12 are interaction energies for the 11 strongest ligand-residue interactions,
most likely caused by steric clashes related to backbone atoms.
with four different ligands, those found in 3KFC, 5HJP, 1PQC (T0901317), and 1PQ6 (GW3965). The
Shown in Figure 12 are interaction energies for the 11 strongest ligand-residue interactions, with
most notable aspect of the data depicted here is that the only ligand-residue interactions that appear to
four different ligands, those found in 3KFC, 5HJP, 1PQC (T0901317), and 1PQ6 (GW3965). The most
be particularly strong for all four systems are the ones involving Phe271 (~4–5 kcal/mol) and His435
notable
of the
data depicted
here
is that
the only
ligand-residue
appear
to be
(~3.5–6aspect
kcal/mol).
Interactions
for the
1PQC
structure
are notably
weak forinteractions
several of thethat
residues
here,
particularly
strong
for
all
four
systems
are
the
ones
involving
Phe271
(~4–5
kcal/mol)
and
His435
which is perhaps not surprising when it is taken into consideration that, although it is known to be a
(~3.5–6
Interactions
the 1PQC
structure
notably in
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several
of the
strongkcal/mol).
agonist, T0901317
is thefor
smallest
of the
ligands are
considered
thisfor
study.
When
the residues
1PQC
here,
which
is
perhaps
not
surprising
when
it
is
taken
into
consideration
that,
although
it
is
known
structure is neglected, it is seen that all ligand-residue interactions, with the only other exceptions to
being 1PQ6/Ala275 and 1PQ6/Leu274, have a binding energy of at least two kcal/mol, meaning that
each of these interactions make significant contributions to ligand binding.
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be a strong agonist, T0901317 is the smallest of the ligands considered in this study. When the 1PQC
structure is neglected, it is seen that all ligand-residue interactions, with the only other exceptions
being 1PQ6/Ala275 and 1PQ6/Leu274, have a binding energy of at least two kcal/mol, meaning that
each of these interactions make significant contributions to ligand binding.
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Figure 12. Interaction energies of 11 selected amino acids with ligands in the binding pocket of LXRβ.
Figure 12. Interaction energies of 11 selected amino acids with ligands in the binding pocket of LXRβ.
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involving the ligand, His435, and Trp 457 are also seen in Figure 10.
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of the
bindinginteractions
pocket.
Here a C-H…π interaction is established between the histidine imidizole ring and the heterocyclic
The important interactions involving the ligand, His435, and Trp 457 are also seen in Figure 10.
ring of the tryptophan indole structure. It is believed that the establishment of this interaction,
Here a C-H . . . π interaction is established between the histidine imidizole ring and the heterocyclic
establishing contact between helix 12 (AF2) and helix 11, is responsible for LXR agonism. In terms of
ring of the tryptophan indole structure. It is believed that the establishment of this interaction,
interactions of the ligand with these residues, there is clearly a N-H···F hydrogen bond between
establishing contact between helix 12 (AF2) and helix 11, is responsible for LXR agonism. In terms
His435 and the ligand CF3 group and a π-π contact between the ligand and Trp457. It should be
of interactions of the ligand with these residues, there is clearly a N-H···F hydrogen bond between
noted that there is also a strong possibility for a (stronger) N-H···N type hydrogen bond to be
His435 and the ligand CF3 group and a π-π contact between the ligand and Trp457. It should be noted
established between His435 and the ligand, and that this type of interaction might also exist.
that there is also a strong possibility for a (stronger) N-H···N type hydrogen bond to be established
Figure 13 shows interactions energies for His435-Trp457, ligand-His435, and ligand-Trp457
between His435 and the ligand, and that this type of interaction might also exist.
contacts. The most interesting aspect of the data depicted here is the fact that the His435-Trp457
Figure 13
showsare
interactions
energies
for His435-Trp457,
ligand-His435,
ligand-Trp457
interaction
energies
fairly strong
(~2.0 kcal/mol
or higher) for
all structures and
except
4DK7 and
contacts.
The
most
interesting
aspect
of
the
data
depicted
here
is
the
fact
that
the
His435-Trp457
4DK8, which both represent partial agonists (the other five structures contain full agonists), which
both have binding energies that are significantly lower. This finding supports the hypothesis that
His435-Trp457 interactions mediate LXR agonism. The relationship between ligand-residue
interactions and LXR agonism is not so clear. For example, ligand-His435 interactions are strong
(above 3.0 kcal/mol) for five of the structures, but are significantly weaker for 3L0E (full agonist) and
4DK8 (partial agonist). Ligand-Trp457 interactions are all in the range from 2.0–4.0 kcal/mol, with no
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interaction energies are fairly strong (~2.0 kcal/mol or higher) for all structures except 4DK7 and 4DK8,
which both represent partial agonists (the other five structures contain full agonists), which both have
binding energies that are significantly lower. This finding supports the hypothesis that His435-Trp457
interactions mediate LXR agonism. The relationship between ligand-residue interactions and LXR
agonism is not so clear. For example, ligand-His435 interactions are strong (above 3.0 kcal/mol) for
five of the structures, but are significantly weaker for 3L0E (full agonist) and 4DK8 (partial agonist).
Ligand-Trp457 interactions are all in the range from 2.0–4.0 kcal/mol, with no particular preference for
full agonists above partial agonists.
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Figure 13. Calculated interaction energies for His435-Trp457, ligand-His435, and ligand-Trp457
Figure 13. Calculated interaction energies for His435-Trp457, ligand-His435, and ligand-Trp457 interactions.
interactions.
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